What's Happening?
A new minimally invasive outpatient procedure, known as duodenal mucosal resurfacing, is showing promise in helping individuals maintain weight loss after discontinuing popular weight-loss medications like Ozempic and semaglutide. According to research
presented at Digestive Disease Week 2026, about 70% of people who stop these medications regain much of the weight they lost, often within 18 months. The procedure involves using controlled heat to remove damaged tissue from the duodenum, encouraging the growth of healthier tissue. This process aims to provide a lasting metabolic reset, helping the body maintain weight loss without ongoing medication. The REMAIN-1 trial, which is testing this procedure, has shown that participants who underwent the treatment regained significantly less weight compared to those who received a sham procedure.
Why It's Important?
The development of this procedure is significant as it addresses a major challenge faced by individuals using GLP-1 medications for weight loss. Many people discontinue these drugs due to cost, side effects, or the desire to avoid long-term medication use, leading to weight regain and loss of metabolic benefits. The duodenal mucosal resurfacing offers a potential solution by providing a way to maintain weight loss and metabolic health without the need for continuous medication. This could have a substantial impact on public health, reducing the burden of obesity-related diseases and improving quality of life for many individuals.
What's Next?
The duodenal mucosal resurfacing procedure is still considered investigational, with the larger REMAIN-1 study fully enrolled and randomized. Researchers expect to release six-month data from the pivotal cohort in the fourth quarter of 2026, with plans for a marketing submission later that year. If successful, this procedure could become a widely adopted method for maintaining weight loss after stopping GLP-1 medications, potentially transforming obesity treatment protocols.
